GSK’s cancer drug Jemperli has received priority review from the U.S. Food and Drug Administration (FDA) following results from a pivotal trial. The trial showed a significant proportion of patients had no detectable signs of rectal tumors for at least one year. This could lead to a major shift in the treatment of certain rectal cancers if approved, potentially allowing patients to avoid chemotherapy, radiation, and surgery.

Potential Changes in Treatment

The FDA has set a decision deadline for February 2027, but the application is eligible for accelerated consideration under the National Priority Voucher program. This means an earlier ruling could occur. The application is also under review via Project Orbis, which facilitates coordinated international approvals.

Results from AZUR-1 Trial

The FDA’s review relies on the AZUR-1 trial, a phase II global study evaluating Jemperli as a standalone treatment for untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The trial met its primary endpoint, showing clinical complete responses lasting at least 12 months according to Hesham Abdullah, GSK’s senior vice president and global head of oncology R&D.

The trial involved 154 patients who received nine cycles of Jemperli over six months. Interim safety data were consistent with the established safety profile of the drug.

Breakthrough in Treatment

Traditionally, treatment for this rectal cancer subtype includes chemotherapy, radiation, and surgery. Although effective for some, these treatments can lead to permanent complications. Abdullah stated that while these treatments aim to cure, they often negatively impact patients’ quality of life and survival.

Jemperli could become the first approved immunotherapy helping some patients eliminate or delay chemotherapy, radiation, and surgery.

Quality-of-Life Improvements

The possibility of avoiding surgery and its irreversible consequences is crucial. Current treatments often come with a heavy personal cost, including the lifelong use of colostomy bags, fertility issues, and various side effects impacting day-to-day life.

Abdullah noted that if Jemperli becomes a first-line option, it could prevent these outcomes for selected patients.

The Mechanism of Action

Building on earlier research from Memorial Sloan Kettering Cancer Center, the AZUR-1 results demonstrated PD-1 blockade without chemoradiation. dMMR/MSI-H tumors carry many genetic changes, making them more visible to the immune system. Jemperli enhances the immune response by removing the ‘brakes’ from immune cells attacking the cancer.

Regulatory Process and Future Steps

The FDA has set a February 2027 PDUFA date. However, expedited review through the National Priority Voucher program might lead to an earlier decision. GSK seeks approval through Project Orbis for simultaneous international review.

Abdullah highlighted this urgency, stating that the combination of priority review, Fast Track designation, Breakthrough Therapy designation, and Orbis participation emphasizes the need for new treatment options.

If approved, biomarker testing must be incorporated earlier in diagnosis, altering treatment strategies to focus on immunotherapy first.

Impact on GSK’s Oncology Program

Jemperli is central to GSK’s expanding oncology portfolio. The company’s shares have increased by 9.7 percent this year, reflecting investor confidence. GSK is advancing Phase 3 trials in gastrointestinal cancers and developing antibody-drug conjugates and targeted therapies.

Interim AZUR-1 results will be shared later this year to inform global regulatory processes. Abdullah stated that ongoing Phase 3 trials in gastrointestinal cancers continue as patient needs and biological advances create opportunities to address care limitations.